Ocugen Inc (NAS:OCGN)

$ 1.42 -0.1 (-6.58%) Market Cap: 365.44 Mil Enterprise Value: 345.90 Mil PE Ratio: 0 PB Ratio: 12.03 GF Score: 34/100

Q1 2024 Ocugen Inc Earnings Call Transcript
May 14, 2024

$1.7 (-6.08%)

Earnings
Q4 2023 Ocugen Inc Earnings Call Transcript
Apr 02, 2024

$1.38 (-10.39%)

Earnings
Q3 2023 Ocugen Inc Earnings Call Transcript
Nov 09, 2023

$0.3685 (-4.11%)

Earnings
Ocugen Inc at Chardan Genetic Medicines Conference Transcript
Oct 02, 2023
Ocugen Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Ocugen Inc to Discuss Updated Results from the Phase 1/2 Trial of OCU400 Investor Call Transcript
Sep 13, 2023
Q2 2023 Ocugen Inc Earnings Call Transcript
Aug 22, 2023

$0.4032 (-8.96%)

Earnings
Ocugen Inc Annual Shareholders Meeting Transcript
Jun 23, 2023
Q1 2023 Ocugen Inc Earnings Call Transcript
May 05, 2023

$0.7 (+0.72%)

Earnings
Ocugen Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Ocugen Inc To Host Virtual Investor & Analyst Event Transcript
Apr 14, 2023
Ocugen Inc at ROTH Conference Transcript
Mar 13, 2023
Q4 2022 Ocugen Inc Earnings Call Transcript
Feb 28, 2023

$0.9962 (+2.07%)

Earnings
Q3 2022 Ocugen Inc Earnings Call Transcript
Nov 08, 2022

$1.64 (+7.19%)

Earnings
Ocugen Inc at Chardan Genetic Medicines Conference Transcript
Oct 04, 2022
Ocugen Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Ocugen Inc at H C Wainwright Ophthalmology Virtual Conference Transcript
Aug 17, 2022
Q2 2022 Ocugen Inc Earnings Call Transcript
Aug 05, 2022

$2.86 (+3.25%)

Earnings
Ocugen Inc Annual Shareholders Meeting Transcript
Jun 07, 2022
Q1 2022 Ocugen Inc Earnings Call Transcript
May 06, 2022

$2.16 (-5.26%)

Earnings
Q4 2021 Ocugen Inc Earnings Call Transcript
Feb 25, 2022

$3.22 (+5.40%)

Earnings
Q3 2021 Ocugen Inc Earnings Call Transcript
Nov 09, 2021

$8.92 (-7.37%)

Earnings
Ocugen Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021
Q2 2021 Ocugen Inc Earnings Call Transcript
Aug 06, 2021

$7.86 (+4.94%)

Earnings
Q1 2021 Ocugen Inc Earnings Call Transcript
May 07, 2021

$9.19 (-4.12%)

Earnings
Q4 2020 Ocugen Inc Earnings Call Transcript
Mar 18, 2021

$8.9 (-6.81%)

Earnings
Ocugen Inc at Noble Financial Small & Microcap Investor Conference (Virtual) Transcript
Jan 20, 2021
Ocugen Inc at Commercializing Transformative Therapies for Blindness Diseases Transcript
Nov 10, 2020
Ocugen Inc at NAI Interactive GCFF Virtual Conference -- Diversified Investing Strategies Transcript
Nov 05, 2020
Ocugen Inc at LD 500 Conference (Virtual) Transcript
Sep 04, 2020
Q2 2020 Ocugen Inc Earnings Call Transcript
Aug 14, 2020

$0.5648 (-9.34%)

Earnings
Q4 2019 Ocugen Inc Earnings Call Transcript
Mar 27, 2020

$0.2999 (-14.31%)

Earnings
Histogenics Corp and Ocugen Inc to Discuss the Merger Agreement Transcript
Apr 08, 2019

Ocugen Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 07:30PM GMT

Release Date Price: $2.45 (-1.21%)

Transcript

Swayampakula Ramakanth

H.C. Wainwright & Co. - Managing Director, Senior Healthcare Analyst

Good afternoon and thanks for joining us to have a conversation with Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that employ health and offer hope for patients across the globe.

The company's lead program in gene therapies, OCU400, is currently in the clinic. Additionally, the company has also entered into a development and commercial agreement with an Indian pharma, Bharat Biotech, to commercialize their whole-variant inactivated COVID-19 vaccine called Covaxin.

Covaxin currently has been approved under an EUA in India. The company has regulatory applications for marketing Covaxin in the US, Canada, and Mexico. Additionally, Ocugen recently initiated a clinical program with NeoCart that currently has RMAT designation. So to learn about the deep pipeline of Ocugen, let's get started with Shankar.

Shankar, glad to see you, and I

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.